Matar Abraham J, Falconer Elissa, LaBella Michelle, Kapadia Muneera R, Justiniano Carla F, Olortegui Kinga Skowron, Steinhagen Randolph, Schultz Kurt, Pratap Anurag, Leeds Ira, Weaver Lauren, Gaertner Wolfgang, Finger Erik B, Thompson Mary, Fair Lucas, Fichera Alessandro, Lovasik Brendan P, Chapman William C, McGeoch Catherine Lb, Camacho Mary Catherine, Kazimi Marwan, Kim Steven C, Shaffer Virginia O, Srinivasan Jahnavi K
Emory University, Atlanta, Georgia.
University of North Carolina, Chapel Hill, North Carolina.
Ann Surg. 2024 Sep 11. doi: 10.1097/SLA.0000000000006533.
To investigate the long-term outcomes of patients with combined primary sclerosing cholangitis/inflammatory bowel disease (PSC-IBD) undergoing both liver transplantation (LT) and total abdominal colectomy (TAC).
The fraction of patients with PSC-IBD that require both LT and TAC is small, thereby limiting significant conclusions regarding long-term outcomes.
Adult and pediatric patients from nine centers from the US IBD Surgery Collaborative who underwent staged LT and TAC for PSC-IBD were included. Long-term outcomes, including survival, were assessed.
Among 127 patients, 66 underwent TAC-before-LT, with a median time from TAC to LT of 7.9 yrs, while 61 underwent LT-before-TAC, with a median time from LT to TAC of 4.4 years. Median patient survival post TAC was significantly worse in those undergoing LT-before-TAC (16.0 yrs vs. 42.6 yrs, P=0.007), while post LT survival was not impacted by the order of TAC and LT (21.6 yrs vs. 22.0 yrs, P=0.81). Patients undergoing TAC for medically refractory disease had a higher incidence of recurrent PSC (rPSC) (P=0.02) and biliary complications (0.09) compared to those undergoing TAC for oncologic indications. Definitive TAC reconstruction with either end ileostomy or ileal-pouch anal anastomosis (IPAA) did not impact post-LT or post-TAC outcomes.
Long term survival in PSC-IBD was contingent upon progression to LT and was not impacted by the need for TAC. PSC-IBD patients undergoing TAC for medically refractory disease had a higher incidence of rPSC and biliary complications. The use of IPAA in PSC-IBD was a viable alternative to end ileostomy.
研究同时接受肝移植(LT)和全腹结肠切除术(TAC)的原发性硬化性胆管炎合并炎症性肠病(PSC-IBD)患者的长期预后。
需要同时进行LT和TAC的PSC-IBD患者比例较小,因此限制了关于长期预后的重要结论。
纳入来自美国炎症性肠病外科协作组9个中心的成年和儿科患者,这些患者因PSC-IBD接受了分期LT和TAC。评估包括生存在内的长期预后。
127例患者中,66例先接受TAC后接受LT,从TAC到LT的中位时间为7.9年,而61例先接受LT后接受TAC,从LT到TAC的中位时间为4.4年。先接受LT后接受TAC的患者TAC术后的中位生存期明显较差(16.0年对42.6年,P=0.007),而LT术后生存不受TAC和LT顺序的影响(21.6年对22.0年,P=0.81)。与因肿瘤适应证接受TAC的患者相比,因药物难治性疾病接受TAC的患者复发性PSC(rPSC)发生率更高(P=0.02),胆道并发症发生率更高(0.09)。采用回肠末端造口术或回肠储袋肛管吻合术(IPAA)进行确定性TAC重建对LT术后或TAC术后结局无影响。
PSC-IBD患者的长期生存取决于是否进展为LT,不受是否需要TAC的影响。因药物难治性疾病接受TAC的PSC-IBD患者rPSC和胆道并发症发生率更高。在PSC-IBD中使用IPAA是回肠末端造口术的可行替代方案。